All In Biotech

NDA 212801 · Recordati Rare

Isturisa

Osilodrostat Phosphate · Oral

NovelOrphan

Last checked: Nov 19, 2026Latest source record: Nov 4, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Mar 6, 2020

Approved uses

3

Original approval plus efficacy supplements

Registered trials

19

2 Phase 3, 6 recruiting

FAERS reports

2,214

1,554 serious, 294 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 18, 2025.

ISTURISA is indicated for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative. ISTURISA is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative ( 1 )

Mechanism: Osilodrostat is a cortisol synthesis inhibitor. It inhibits 11beta-hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland. In a Chinese hamster lung cell line V79-4 that overexpresses human CYP11B1, adrenodoxin and adrenodoxin reductase, osilodrostat inhibited the activity of human CYP11B1 dose-dependently with IC50 values of 2.5 ± 0.1 nM (n = 4).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 3, 2025 Supplement 4 · Efficacy OrphanLetterLabel
  • Apr 15, 2025 Supplement 3 · Efficacy OrphanLetterLabel
  • Mar 6, 2020 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
3 products under this application
  • ISTURISA · OSILODROSTAT PHOSPHATE EQ 5MG BASE · TABLET, ORAL · Prescription
  • ISTURISA · OSILODROSTAT PHOSPHATE EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • ISTURISA · OSILODROSTAT PHOSPHATE EQ 1MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Osilodrostat" as an intervention, any sponsor and status, largest first.

All 19 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use376
  • fatigue305
  • nausea260
  • death152
  • adrenal insufficiency142
  • headache142
  • asthenia129
  • diarrhoea125
  • dizziness120
  • decreased appetite114
  • vomiting109
  • cortisol decreased88

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20181
2020160
2021148
2022268
2023281
2024400
2025544
2026412

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Isturisa (Osilodrostat Phosphate)

2024 spending

$65.5M

Beneficiaries

328

2,284 claims

Per beneficiary

$199,763

$249.21 per unit

View as table
YearSpending
2020$2,176,243
2021$9,457,234
2022$17,110,721
2023$34,621,980
2024$65,522,308

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 23 on PubMed

Sponsor: Recordati Rare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.